Multidrug Resistance Proteins in Renal Cell Carcinoma Cited by

Fol. Biol. 2008, 54, 187-192

https://doi.org/10.14712/fb2008054060187

Multidrug Resistance Proteins in Renal Cell Carcinoma

Ingrid Hodorová¹, S. Rybárová¹, P. Solár², J. Vecanová¹, J. Mihalik¹, P. Bohuš³, Y. Mellová⁴, D. Kluchová¹

¹Department of Anatomy, Faculty of Medicine, P. J. Šafárik University in Košice, Košice, Slovak Republic
²Department of Cell Biology, Faculty of Medicine, P. J. Šafárik University in Košice, Košice, Slovak Republic
³Department of Pathological Anatomy, Faculty of Medicine, P. J. Šafárik University in Košice, Košice, Slovak Republic
⁴Department of Anatomy, Jessenius Faculty of Medicine, Comenius University, Martin, Slovak Republic

Received August 2008
Accepted November 2008

Crossref Cited-by Linking

Abt Dominik, Besse Andrej, Sedlarikova Lenka, Kraus Marianne, Bader Juergen, Silzle Tobias, Vodinska Martina, Slaby Ondrej, Schmid Hans\u2010Peter, Engeler Daniel Stephan, Driessen Christoph, Besse Lenka: Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)\u2010protease inhibitors lopinavir or nelfinavir. BJU International 2018, 121, 600. <https://doi.org/10.1111/bju.14083>
Thompson J M, Nguyen Q H, Singh M, Pavesic M W, Nesterenko I, Nelson L J, Liao A C, Razorenova O V: Rho-associated kinase 1 inhibition is synthetically lethal with von Hippel-Lindau deficiency in clear cell renal cell carcinoma. Oncogene 2017, 36, 1080. <https://doi.org/10.1038/onc.2016.272>
Porta Camillo, Toscani Ilaria, Czarnecka Anna M., Szczylik Cezary A.: Immuno-oncology for renal cell carcinoma treatment: future perspectives for combinations and sequences with molecularly targeted agents. Expert Opinion on Biological Therapy 2017, 17, 151. <https://doi.org/10.1080/14712598.2017.1271869>
Shenoy N., Pagliaro L.: Sequential pathogenesis of metastatic VHL mutant clear cell renal cell carcinoma: putting it together with a translational perspective. Annals of Oncology 2016, 27, 1685. <https://doi.org/10.1093/annonc/mdw241>
Shen Kunyu, Johnson David W., Gobe Glenda C.: The role of cGMP and its signaling pathways in kidney disease. American Journal of Physiology-Renal Physiology 2016, 311, F671. <https://doi.org/10.1152/ajprenal.00042.2016>
Park Eun Jung, Chauhan Anil Kumar, Min Kyoung-Jin, Park Dong Cheol, Kwon Taeg Kyu: Thymoquinone induces apoptosis through downregulation of c-FLIP and Bcl-2 in renal carcinoma Caki cells. Oncology Reports 2016, 36, 2261. <https://doi.org/10.3892/or.2016.5019>
Adamkov Marian, Výbohová Desanka, Tupá Veronika, Chylíková Jaroslava, Horá\u010dek Jaroslav, Ben\u010dat Marián: Expression and significance of survivin in colorectal high grade and low grade adenomas. Acta Histochemica 2015, 117, 590. <https://doi.org/10.1016/j.acthis.2015.05.006>
Kunická Tereza, Sou\u010dek Pavel: Importance of ABCC1 for cancer therapy and prognosis. Drug Metabolism Reviews 2014, 46, 325. <https://doi.org/10.3109/03602532.2014.901348>
Yang Jian, Nagasawa Daniel T., Spasic Marko, Amolis Misha, Choy Winward, Garcia Heather M., Prins Robert M., Liau Linda M., Yang Isaac: Endogenous Vaults and Bioengineered Vault Nanoparticles for Treatment of Glioblastomas. Neurosurgery Clinics of North America 2012, 23, 451. <https://doi.org/10.1016/j.nec.2012.04.012>
Liu Qian, Zhang Hao, Smeester Lisa, Zou Fei, Kesic Matt, Jaspers Ilona, Pi Jingbo, Fry Rebecca C: The NRF2-mediated oxidative stress response pathway is associated with tumor cell resistance to arsenic trioxide across the NCI-60 panel. BMC Med Genomics 2010, 3. <https://doi.org/10.1186/1755-8794-3-37>
Ji Zhengang, Long Hua, Hu Yunsheng, Qiu Xiuchun, Chen Xiang, Li Zhao, Fan Degang, Ma Baoan, Fan Qingyu: Expression of MDR1, HIF-1\u03b1 and MRP1 in sacral chordoma and chordoma cell line CM-319. J Exp Clin Cancer Res 2010, 29. <https://doi.org/10.1186/1756-9966-29-158>